Skip to main content Skip to main navigation menu Skip to site footer

Journal of Ideas in Health

Articles
DOI: 10.47108/jidhealth.Vol6.Iss4.321
Submitted: 2023-10-23
Published: 2023-12-31

Bridging the diagnostic gap: liver function tests and IL-6 as potential early predictors of non-alcoholic fatty liver disease in psoriasis

Department of Microbiology, College of Medicine, University of Diyala, Diyala, Iraq
Department of Microbiology, College of Medicine University of Diyala, Diyala, Iraq
Department of Family and Community Medicine, College of Medicine, University of Diyala, Diyala, Iraq
Medical Immunology, College of Medicine, University of Diyala, Diyala, Iraq
Department of Medicine, College of Medicine, University of Diyala, Diyala, Iraq.
Department of Microbiology, College of Medicine University of Diyala, Diyala, Iraq
P. aeruginosa, ERIC-PCR, ESBLs, fingerprint analysis

Abstract

Background: Psoriasis goes beyond skin, intertwining with body systems, notably connecting to nonalcoholic fatty liver disease (NAFLD). This study aims to explore the predictive potential: liver function tests and IL-6 as early markers for non-alcoholic fatty liver disease in psoriasis patients. 

Methods: From March to November 2023, a case-control study was performed at the dermatological outpatient clinic of Baquba Teaching Hospital, Iraq. Individuals with confirmed psoriasis and those without underwent comprehensive clinical history and overall health examinations. The diagnosis of non-alcoholic fatty liver disease (NAFLD) was established using the Fatty Liver Index (FLI).

Results: Among the 290 participants in this study, 103 with confirmed psoriasis displayed a Fatty Liver Index (FLI) score >60, indicative of non-alcoholic fatty liver disease (NAFLD). The control group, comprising 101 individuals without psoriasis or NAFLD, provided a baseline for comparison. The mean ages were 32.5 ± 16.2 and 31.5 ± 14.3 years for the case and control groups, respectively. Notably, the case group exhibited significantly higher mean ± SD levels of ALT and AST (61 ± 29 vs. 33 ± 17 U/L, p < 0.0001) and (55 ± 27 vs. 25 ± 15 U/L, p < 0.0001), respectively. Moreover, FLI criteria were markedly elevated in the case group (p = 0.0007, p = 0.0005, p < 0.0001, and p < 0.0001, respectively), and IL-6 levels were significantly higher (p = 0.0003).

Conclusion: The results proposed that liver function tests and IL-6 could act as early predictors for the detection of non-alcoholic fatty liver disease among individuals grappling with psoriasis.



Downloads

Download data is not yet available.

References

  1. Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022 Jun 10; 13:880201. doi: 10.3389/fimmu.2022.880201.
  2. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009 Jan;13(1):9-19.
  3. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol. 2015 Mar 27;7(3):315-26. doi: 10.4254/wjh.v7.i3.315.
  4. Klujszo EH, Parcheta P, Witkowska AB, Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol. 2020 Aug;37(4):468-474. doi: 10.5114/ada.2019.83983.
  5. Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci. 2016 Feb 5;17(2):217. doi: 10.3390/ijms17020217.
  6. Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. International Journal of Molecular Sciences. 2022; 23(14):7499. https://doi.org/10.3390/ijms23147499.
  7. Prussick R, Prussick L, Nussbaum D. Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know. J Clin Aesthet Dermatol. 2015 Mar;8(3):43-5.
  8. Gau SY, Huang KH, Lee CH, Kuan YH, Tsai TH, Lee CY. Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies. Front Immunol. 2022 Feb 16;13:840106. doi: 10.3389/fimmu.2022.840106.
  9. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. 2011;2011:721608. doi: 10.1155/2011/721608.
  10. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.
  11. Murad AAK, Hussien WM. Incidence of psoriasis in patients with different skin diseases in Baquba City. Diyala Journal of Medicine 2017; 12(1): 25-28.‏
  12. Al Samarai AG. Prevalence of skin diseases in Iraq: a community based study. Int J Dermatol. 2009 Jul;48(7):734-9. doi: 10.1111/j.1365-4632.2009.03812.x.
  13. Torres T, Bettencourt N. Psoriasis: the visible killer. Rev Port Cardiol. 2014 Feb;33(2):95-9. doi: 10.1016/j.repc.2013.06.017.
  14. Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, Xie X. Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults. JAMA Dermatol. 2022 Jul 1;158(7):745-753. doi: 10.1001/jamadermatol.2022.1609.
  15. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722-727. doi: 10.1111/ced.12672.
  16. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-764. doi: 10.1016/j.jhep.2009.04.020.
  17. Narayanasamy K, Sanmarkan AD, Rajendran K, Annasamy C, Ramalingam S. Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol. 2016;11(4):263-269. doi: 10.5114/pg.2015.53376.
  18. van der Voort EAM, Koehler EM, Dowlatshahi EA, et al.. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70(3):517-524. doi: 10.1016/j.jaad.2013.10.044.
  19. Dhurgham A. Mahmood, et al. Evalution of Liver Function Tests in Patients with Psoriasis. Revista Latinoamericana de Hipertensión 2022;17(6):397-403. DOI: https://doi.org/10.5281/zenodo.7406087.
  20. Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019 Mar 18;6(1):41. doi: 10.3390/medicines6010041.
  21. Atzeni F, Ventura D, Batticciotto A, Boccassini L, Sarzi-Puttini P. Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J Rheumatol Suppl. 2012;89:97–9. https://doi.org/10.3899/jrheum.120256.
  22. Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017;27:137–41. https://doi.org/10.3109/14397595.2016.1174328.


How to Cite

1.
Adbullah T, Ali A, Ali Jadoo SA, Latif I, Alkayally KKA, Salman R. Bridging the diagnostic gap: liver function tests and IL-6 as potential early predictors of non-alcoholic fatty liver disease in psoriasis . jidhealth [Internet]. 2023 Dec. 31 [cited 2024 May 18];6(4):990-4. Available from: https://www.jidhealth.com/index.php/jidhealth/article/view/321

issn

Journal of Ideas in Health

Four Issues Annually

www.jidhealth.com

eISSN: 2645-9248

Founded: 2017

call

Make a Submission

Make a Submission

ToBeRev

road

google

pkpindex

oai

base

tools



cc

doaj

mendeley

doi

jisc

Keywords